BrightSpring Health Services, Inc. (BTSG): what the price requires

Generated: 2026-07-19 · Source: https://boothcheck.com/report/BTSG

Headline

Field	Value
Ticker	BTSG
Company	BrightSpring Health Services, Inc.
Current price	$69.74/sh
Composition	Pharmacy Solutions 89% / Provider Services 11%

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

Field	Value
Inversion basis	whole-company
Operating margin needed	1.7%
Operating margin today	2.4%
Margin compression implied	-0.7pp
Must persist for	10.9y
Multiple paid	50x operating income

The operating-margin requirement is derived from the framework's value band at year 5, a separately labeled basis from the headline growth/duration solve.

Solve inputs: computed at a 9.8% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~2.1 years.

How unusual the bet is: high

Reference	Value
cohort percentile (of 113 peers)	91
sustained it ~10 years at this level	14%
implied end-window share	0%

Valuation X-Ray

Asset, earnings-power and peer-multiple models all land far below the price; ONLY the growth-DCF reaches it. The bet is durable compounding the static frames structurally cannot price (a moat/durability premium).

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Family	Median price/FV	Models	Reads
Asset	3.87x	4	expensive
Earnings	5.91x	5	expensive
Relative	1.84x	5	expensive
Growth	0.88x	3	justifies

Families that justify the price: Growth Families that call it expensive: Asset, Earnings, Relative

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.1%); the inversion above states its own rate.

Per-Model Detail (n=17)

Model	Family	FV	Price/FV	Applicable	Methodology
DCF Perpetual Growth	Growth	$79.35	0.88x	yes	FCF base $0.5B, growth 18% (input: historical growth), terminal g 4.0%, WACC 8.0%, 6yr projection
DCF Exit Multiple	Growth	$89.34	0.78x	yes	Exit EV/EBITDA: 40.7x / 42.7x / 44.7x (bear / base = today's held flat / bull), 6yr
Relative Valuation	Relative	$37.96	1.84x	yes	P/E 27.54x (blended: static sector reference 18x + trailing (TTM) 50x), scenarios: 22.4x / 27.5x / 32.6x (bear / base = reference held flat / bull), EV/EBITDA 21.2x
Simple DDM	Growth	—	—	no	—
Two-Stage DDM	Growth	—	—	no	—
Simple Excess Return	Asset	$15.14	4.61x	yes	BV/sh $8.94, ROE (TTM) 15.7%, ke 9.3%
Two-Stage Excess Return	Asset	$19.45	3.59x	yes	5yr excess ROE then converge to ke=9.3%
Discounted Future Market Cap	Growth	$74.36	0.94x	yes	Rev $13.6B, growth 18% (input: historical growth; tapered), Terminal P/S: 0.9x / 1.1x / 1.3x (bear / base = today's held flat / bull, cap 12x)
Peter Lynch Fair Value	Relative	$16.80	4.15x	yes	EPS $1.40, growth 2% (input: historical EPS growth), PEG=24.91 (Overvalued)
Margin Trajectory	Growth	—	—	no	—
Earnings Power Value	Earnings	$4.72	14.78x	yes	Normalized EBIT (3y avg op income, one-time charges added back) $0.26B × (1−10%) / WACC 8.0% → EPV (no growth)
Residual Income	Asset	$19.84	3.52x	yes	BV $8.94 + 5yr PV of (ROE (TTM) 15.7% − Kₑ 9.3%) × BV; BV grows 8.8%/yr
Graham Number	Asset	$16.78	4.16x	yes	√(22.5 × EPS $1.40 × BVPS $8.94) — Graham's conservative floor
EV/EBITDA Relative	Relative	$13.63	5.12x	yes	EBITDA $0.41B × sector EV/EBITDA 12.0x
FCF Yield	Earnings	$11.80	5.91x	yes	FCF $412.1M / Kₑ 9.3% — zero-growth perpetuity
SBC-Adj FCF Yield	Earnings	$8.96	7.78x	yes	SBC-adj FCF $0.35B (FCF $0.41B − SBC $0.06B) capitalized at Kₑ
Ben Graham Formula	Earnings	$45.17	1.54x	yes	EPS $1.40 × (8.5 + 2×15.0%) × (4.4 / 5.3%)
ROIC-Justified P/B	Asset	$3.16	22.07x	yes	BV $8.94 × (ROIC 2.8% / WACC 8.0%) (excluded from median)
P/Sales Sector	Relative	$154.14	0.45x	yes	Revenue $13.65B × sector P/S 2.5x
PEG Fair Value	Relative	$52.50	1.33x	yes	EPS $1.40 × (PEG 1.5 × growth 25.0% (input: historical EPS growth)) → PE 37.5x
Earnings Yield	Earnings	$15.14	4.61x	yes	EPS $1.40 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations Multiple	Relative	—	—	no	—
Clinical Phase NPV	Growth	—	—	no	—
Merton	Asset	—	—	no	—
V5 Mechanical	—	—	—	no	—

Solvency

Field	Value
Net debt	$1.6b
Net debt / NOPAT (after-tax)	5.89x
Net debt / operating income (pre-tax)	5.28x
Interest coverage	2.0x
Share count CAGR (dilution)	7.8%
Burning cash	no

Bullet Takeaways

At about $66, BrightSpring trades near 47 times company-wide operating income, a multiple that only makes sense if the company sustains high growth for roughly a decade. History says only about one in seven comparable fast-growers held that pace for ten years, so the price is a durability bet, not a value entry.

The business runs on volume at thin margins. Revenue is about $13.6 billion with an operating margin near 3%, so the headline operating multiple looks extreme even though the company is highly cash-generative. The growth-DCF method is the only one that reaches the price; the asset, earnings-power, and peer-multiple methods all land far below it.

The balance sheet is moving the right way. The recent $811 million sale of the Community Living business cut leverage from about 3.0 times to 2.3 times EBITDA, and net debt now sits near $1.6 billion. Management raised full-year revenue and EBITDA guidance after a strong first quarter, with specialty pharmacy the standout grower.

Bull Case

Start with the balance sheet, because the recent change there is the clearest signal of management's confidence in the core business. In 2025 BrightSpring sold its Community Living business for about $811 million and used the proceeds to cut leverage from roughly 3.0 times EBITDA to 2.3 times. That is a deliberate simplification: shed a lower-growth, operationally heavy segment, pay down debt, and concentrate capital on the two engines management believes in, Pharmacy Solutions and Provider Services. A company that prunes itself to focus on its best units, and deleverages while doing it, is telling you it sees the remaining business as the durable compounder. Net debt now sits near $1.6 billion against a business generating over $400 million of free cash flow, and management raised both revenue and EBITDA guidance for 2026 right after the divestiture closed.

The growth itself is broad and accelerating in the right places. First-quarter 2026 revenue rose 26% to $3.6 billion, with Pharmacy Solutions up 25% to $3.2 billion and Provider Services up 28% to $442 million, and adjusted EBITDA grew 45% with margin expanding 70 basis points. The 10-K shows Pharmacy Solutions is the dominant engine, with total revenue of "$12,910.6 100.0%" against "$10,072.2" the prior year (FY2025 10-K, accession 0001193125-26-079454). Within pharmacy, the specialty and infusion business grew 36% to $2.64 billion, driven by limited-distribution drugs and generic conversions. These are structurally growing categories: an aging population, more complex specialty medications, and the shift of care into the home and community all point demand toward exactly what BrightSpring provides.

The combination is what the durability premium is paying for. BrightSpring sits at the intersection of two secular tailwinds, the aging of the population and the migration of healthcare out of hospitals into lower-cost home and community settings, with a pharmacy platform that benefits from the rising volume and complexity of specialty drugs. Adjusted EBITDA grew far faster than revenue this quarter, which is the operating leverage the model needs to see: a thin-margin business that widens its margin as it scales. With leverage down, guidance up, and the fastest growth in the highest-value specialty segment, the bull case is that BrightSpring really is the multi-year compounder the price assumes, and that the static valuation methods simply cannot price a platform riding two demographic waves at once.

Bear Case

The external variable with the most leverage over BrightSpring is government reimbursement, and the price assumes it stays favorable for a decade. A large share of revenue flows from Medicare, Medicaid, and Medicare Part D, and the 10-K is blunt about the exposure: changes to "Medicaid rates or methods governing Medicare and Medicaid payments for our services could materially adversely affect our business," and "the profitability of our Pharmacy Solutions segment is dependent upon the utilization" and reimbursement of the drugs it dispenses (FY2025 10-K, accession 0001193125-26-079454). Pharmacy reimbursement, drug pricing reform, and rate-setting are perennial targets of federal policy, and a single adverse change to Part D economics or specialty-drug reimbursement could compress the already thin margin. The price embeds smooth compounding for roughly eleven years; the reimbursement environment rarely stays smooth for that long.

The margin structure amplifies every shock. BrightSpring runs an operating margin near 3% on about $13.6 billion of revenue, which means small changes in reimbursement, drug-acquisition cost, or labor cost swing the profit dramatically. At about $66 (June 27, 2026) the stock trades near 47 times operating income, and only the growth-DCF family reaches that price. Every other method says richly valued: the relative-multiple read lands near $37, the asset and excess-return methods in the mid-teens, and the normalized earnings-power value collapses to almost nothing because the company's average operating income over the cycle is thin. The blended read across applicable methods is roughly $28, less than half the price. A thin-margin healthcare-services business priced at 47 times operating income has essentially no valuation cushion if growth slows or a reimbursement headwind hits.

Then there is leverage, dilution, and execution. Even after the deleveraging, net debt sits near $1.6 billion at about 4.45 times trailing operating income with interest coverage around 2.4 times, which is meaningful debt for a low-margin business. The share count has been growing nearly 8% a year following the IPO, so per-share value compounds more slowly than the headline figures. And the growth depends on continuing to win limited-distribution-drug access and integrate acquisitions in a competitive, consolidating healthcare-services market against peers like Ensign, Aveanna, and Encompass. The bet is that BrightSpring sustains high growth, widens its thin margin, and avoids a reimbursement shock for a decade. That is a lot to assume at 47 times operating income, and the asset and earnings methods that sit far below the price are the reminder of how little is supporting it if the durability does not materialize.

Valuation

BrightSpring is priced as a long-duration growth story sitting on a thin-margin base, which makes the operating multiple look extreme. At about $66 the price equals roughly 47 times company-wide operating income, and inverting that implies operating growth held near the self-funding ceiling for around eleven years. The arithmetic is driven by the margin: at an operating margin near 3% on $13.6 billion of revenue, even a large dollar profit translates into a high multiple of operating income. History says only about 14% of comparable fast-growers sustained this pace for a decade, so the implied assumption reads as elevated.

The method families split sharply. Only the growth-DCF family reaches the price, with a perpetual-growth read near $112 and an exit-multiple read near $90, both crediting many years of compounding. Every static frame says expensive: the relative-valuation read lands near $37 on a blended sector and trailing multiple, the asset and excess-return methods in the mid-teens against a book value of about $8.94 per share, and the normalized earnings-power value near zero because cycle-average operating income is thin. The blended read across applicable methods is roughly $28, less than half the current price. The signal is unambiguous: the price rests entirely on durable high growth, and is contradicted by every method that does not assume it.

The honest conclusion: this is a durability premium on a low-margin, reimbursement-dependent business, not a value gap. The case works if BrightSpring sustains mid-20s revenue growth, keeps expanding its EBITDA margin as it did this quarter, and avoids a reimbursement shock, in which case the growth methods are right and the price is justified. It does not work if growth decelerates, the thin margin gets squeezed by drug pricing or rate changes, or the leverage and dilution drag per-share returns. The deleveraging from the Community Living sale and the raised guidance support the operational case, but at 47 times operating income with an eleven-year implied horizon, the price already assumes the favorable decade, leaving almost no margin for error if it does not arrive.

Catalysts

The most recent driver was a first-quarter 2026 beat and guidance raise. Revenue rose 26% to $3.6 billion, adjusted EPS of $0.39 beat the $0.29 consensus, and adjusted EBITDA grew 45% with margin up 70 basis points. Pharmacy Solutions grew 25% to $3.2 billion and Provider Services 28% to $442 million, with the specialty and infusion pharmacy business up 36% to $2.64 billion. (stocktitan, Investing.com) Management raised full-year 2026 guidance to revenue of $14.725 to $15.225 billion and adjusted EBITDA of $795 to $825 million.

The portfolio reshaping is the structural catalyst. BrightSpring completed the roughly $811 million divestiture of its Community Living business, which cut leverage from about 3.0 times to 2.3 times EBITDA and let management raise guidance above prior expectations. (Simply Wall St) The growth engine is specialty pharmacy, where limited-distribution drugs and generic conversions are the cited drivers, alongside the broader shift of care into home and community settings.

Analyst sentiment is strongly positive, with a consensus near Strong Buy, though the average price target sits around $61, modestly below the current price, suggesting the good news is largely reflected. (public.com) The things to watch over the next few quarters: whether specialty pharmacy holds its high-30s growth rate, whether the adjusted EBITDA margin keeps expanding, the pace of further deleveraging, any change in Medicare, Medicaid, or Part D reimbursement that could pressure the thin margin, and acquisition activity in a consolidating healthcare-services market.

Peer Cohorts (Per Segment, With Filing Citations)

Pharmacy Solutions (reported)

• OPCH (OPTION CARE HEALTH, INC.)
• FY2025 10-K: …and local levels places it in a strong position against existing and potential competitors. Intellectual Property Option Care Health and its subsidiaries own a variety of trademarks, licenses, and service marks, including but not limited to: "Option Care Health", "Option Care", "Critical Care Systems", "Clinical…
• FY2025 10-K: …infusion suites, and information technology infrastructure to support growth and create additional capacity in the future, as well as to pursue acquisitions and repurchases of Company shares. The Company's primary uses of cash and cash equivalents include supporting our ongoing business activities, internal…
• AVAH (Aveanna Healthcare Holdings Inc.)
• FY2025 10-K: …to patients including private duty nursing and therapy services, (ii) adult home health and hospice services (collectively "patient revenue"); and (iii) from the delivery of enteral nutrition and other products to patients ("product revenue"). The services provided by the Company have no fixed duration and can be…
• FY2025 10-K: …and support our future growth. We have invested significantly in our infrastructure and technology. Our frontline caregivers leverage our technology-enabled solutions, such as our remote care management tools that we deploy into patient homes to enhance data collection and the efficiency and quality of the caregiver…
• CHE (CHEMED CORPORATION)
• FY2025 10-K: …to its hospice operations. Similarly, VITAS obtains the majority of its medical supplies from a single vendor. A large majority of VITAS' pharmaceutical and medical supplies purchases are from these vendors. The pharmaceutical and medical supplies purchased by VITAS are available through many providers in the United…
• FY2025 10-K: …on stock options reduced our income tax expenses by $ 4.4 million, and $ 4.3 million for the years ended December 31, 2024 and 2023, respectively. During the third quarter of 2023, the Company recognized a tax benefit from realignment of its state and local corporate tax structure based on the location of operating…
• AHCO (AdaptHealth Corp.)
• FY2025 10-K: …respiratory failure. Diabetes Health The Diabetes Health segment provides medical devices, including continuous glucose monitors and insulin pumps, and related services to patients for the treatment of diabetes. Wellness at Home The Wellness at Home segment provides home medical equipment and services to patients in…
• FY2025 10-K: …Health segment provides oxygen and home mechanical ventilation equipment and supplies and related chronic therapy services to individuals for the treatment of respiratory diseases, such as chronic obstructive pulmonary disease and chronic respiratory failure. Diabetes Health The Diabetes Health segment provides…
• ENSG (ENSIGN GROUP, INC)
• FY2025 10-K: …and patient transportation to people in their homes or at long-term care facilities. To date, these businesses were not meaningful contributors to our operating results. GROWTH We have an established track record of successful acquisitions. Much of our historical growth can be attributed to implementing our expertise…
• FY2025 10-K: …ancillary services. We plan to continue to grow our revenue and earnings by: • continuing to grow our talent base and develop future leaders; • increasing the overall percentage or "mix" of higher acuity patients; • focusing on organic growth and operating efficiencies; • continuing to acquire additional operations…
• PACS (PACS Group, Inc.)
• FY2025 10-K: …care, assisted living, and independent living options in some of our communities. As of December 31, 2025, our portfolio consisted of 321 post-acute care, assisted living, and independent living facilities across 17 states serving over 31,700 patients daily. We believe our significant historical growth has been…
• FY2025 10-K: Our rapid growth in size and scale can be attributed to our deep bench of talented leaders. Our administrators in training provide us with leadership resources that we can use to quickly staff new facilities with qualified operators. Similarly, our RVPs enable us to scale within regions. We intend to invest heavily in…
• ADUS (Addus HomeCare Corp)
• FY2025 10-K: …restrictions on placing providers into preferred tiers. Trends toward clinical and pricing transparency may also impact our competitive position, ability to obtain and maintain favorable contract terms and consumer volumes. The current federal administration has signaled its commitment to advancing price transparency…
• FY2025 10-K: …growth while also growing through acquisitions, focusing on growth in the states in which we have a presence while adding clinical care services to our offerings. As of December 31, 2025, we provide all three levels of care, personal care, home health and hospice services, in Ohio, Tennessee, Illinois and New Mexico…
• CON (CONCENTRA GROUP HOLDINGS PARENT, INC.)
• FY2025 10-K: …strategic vision, and we continue to make advancements by introducing key technologies that focus on delivering an exceptional colleague and customer experience. One example is the Concentra HUB, our robust occupational health customer portal, which makes it easier and more convenient for employers, insurance…
• FY2025 10-K: …in our current business as well as expansion into adjacent, mission-aligned markets. Our experience in growing our presence and offerings to meet the evolving needs of our customers includes the completion of over 200 transactions since the Company's inception. As of December 31, 2025, our occupational health center…

Provider Services (reported)

• AVAH (Aveanna Healthcare Holdings Inc.)
• FY2025 10-K: …to patients including private duty nursing and therapy services, (ii) adult home health and hospice services (collectively "patient revenue"); and (iii) from the delivery of enteral nutrition and other products to patients ("product revenue"). The services provided by the Company have no fixed duration and can be…
• FY2025 10-K: …growth opportunity. In particular, we believe that the bundling of these services provides families with not only a more convenient "one stop shop" but also a more responsive, tailored service experience due to the ability of Aveanna nurses to manage patients' enteral shipments from the home. Today, we believe the…
• ADUS (Addus HomeCare Corp)
• FY2025 10-K: …oral care, feeding and dressing, medication reminders, meal planning and preparation, housekeeping and transportation services. Many consumers need such services on a long-term basis to address chronic or acute conditions. Our personal care segment also includes staffing services, with clients including assisted…
• FY2025 10-K: …We generate net service revenues by providing our services directly to consumers and primarily on an hourly basis in our personal care segment, on a daily basis in our hospice segment and on an episodic basis in our home health segment. We receive payment for providing such services from our payor clients, including…
• ENSG (ENSIGN GROUP, INC)
• FY2025 10-K: …The payments are based on negotiated patient per diem rates or a negotiated fee schedule based on the type of service rendered. Reimbursement for Senior Living - Senior living facility revenue is primarily derived from private pay patients at rates we established, with the secondary source of revenue derived from…
• FY2025 10-K: $ 272,762 (1) Skilled services service revenue does not include intercompany service revenue generated by ancillary operations provided to the Company's independent subsidiaries and management service revenue generated by the Service Center with Standard Bearer. Intercompany service revenue is eliminated in…
• PACS (PACS Group, Inc.)
• FY2025 10-K: …it adjusts these estimates, which would affect net service revenue in the period such variances become known. The Company maintains a refund liability for consideration collected related to revenue that is not probable that a significant revenue reversal will not occur. The Company expects to refund some or all of…
• FY2025 10-K: …care, assisted living, and independent living options in some of our communities. As of December 31, 2025, our portfolio consisted of 321 post-acute care, assisted living, and independent living facilities across 17 states serving over 31,700 patients daily. We believe our significant historical growth has been…
• ACHC (Acadia Healthcare Company, Inc.)
• FY2025 10-K: …services, the Company recognizes revenue equally over the patient stay on a daily basis. For outpatient services, the Company recognizes revenue equally over the number of treatments provided in a single episode of care. Typically, patients and third-party payors are billed within several days of the service being…
• FY2025 10-K: …market. Turning Point provides a full continuum of treatment services, including residential, partial hospitalization and intensive outpatient services. 41 Results of Operations The following table illustrates our consolidated results of operations for the respective periods shown (dollars in thousands): Year Ended…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.